Nemera has a proven track record in developing and manufacturing complex Ear, Nose and Throat solutions. In line with clear growing market interest in unidose system coupled with promising advantages that nasal route could offer, Nemera is thrilled to extend its portfolio by launching its unidose system, UniSpray, for systemic-acting drug administration to face emergency and crisis.
Other than treating conditions locally, nasal delivery is an attractive option to also administer systemic therapies which may vary from benign to serious health conditions. What’s more, is that the nasal route is not invasive and does not require healthcare professionals’ intervention where patients can self-administer their remedy with a rapid onset.
UniSpray is a ready-to-use primeless device with single-metered liquid dose delivery. It offers one-handed activation with 360° functionality to face emergencies and crises. Thanks to its ergonomic design, it is intuitive and easy to-use.
UniSpray is a unidose system concept under development, designed to be robust and compatible with existing marketed primary containers. Through usability analysis and Freedom to Operate assessment, we assure reliability and regulatory compliance of our unidose concept.
Bernhard Rohn, VP Strategy and Marketing commented: “Nemera has a longstanding experience in the nasal delivery route, focusing, until now, on multidose pumps. Adding UniSpray to our product range provides additional options for our customers and patients, answering the needs of the single-metered dose spray combination products”
Raphaële Audibert, Global Category Manager – ENT, added: “This is a great milestone for us. The increasing patient preference for nasal drug delivery as a result of easy administration and better efficacy, as well as growing adoption of self-administration practices, are some of the key factors driving the growth of the nasal market.”
Come discover UniSpray at CPhI Worldwide in Milan, from 9th to 11th November, at booth 6J42.
UniSpray at a glance:
BENEFITS
- Intuitive and robust device with ergonomic finger rest
- Broad labelling surface
- Safe and secured with no risk of accidental activation
- Accelerates time-to-market thanks to possible adaptations to conventional filling lines
- Equivalent utilisation and performance as originators thanks to our in-vitro bioequivalence capability
KEY FEATURES
- Ready-to-use, primeless device, 360° functionality
- Compatible with existing primary drug container
- Single-dose liquid delivery device with one accurate 100µL dose
- Compliant to regulatory exigence
- Customisation possibilities
- For new and repurposed drugs, as well as generics
Find Nemera on the web at www.nemera.net
As a world-leading drug delivery device solutions provider, our purpose of putting patients first enables us to design and manufacture devices that maximise treatment efficacy.
We are a holistic partner and help our customers succeed in the sprint to market their combination products. From early device strategy to state-of-the-art manufacturing, we’re committed to the highest quality standards.
Agile and open-minded, we work with our customers as colleagues. Together, we go the extra mile to fulfil our mission.
